We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $21.7B
1-Year Est. Return 79.24%
This Fund
S&P 500
This Quarter Est. Return
+18.01%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$23.1B
AUM Growth
-$1.32B
Cap. Flow
-$3.13B
Cap. Flow %
-13.54%
Top 10 Hldgs %
44.45%
Holding
175
New
31
Increased
22
Reduced
37
Closed
21

Top Buys

Rank Stock Value
1
EA
Electronic Arts
EA
+$1.02B
2
EXAS
Exact Sciences
EXAS
+$514M
3
CYBR
CyberArk
CYBR
+$507M
4
SNPS icon
Synopsys
SNPS
+$444M
5
AVGO icon
Broadcom
AVGO
+$319M

Top Sells

Rank Stock Value
1
ADSK icon
Autodesk
ADSK
+$528M
2
TMO icon
Thermo Fisher Scientific
TMO
+$352M
3
TRU icon
TransUnion
TRU
+$333M
4
INTU icon
Intuit
INTU
+$333M
5
K
Kellanova
K
+$323M

Sector Composition

Rank Sector Weight
1 Healthcare 41.06%
2 Technology 12.67%
3 Financials 9.75%
4 Communication Services 8.88%
5 Consumer Discretionary 4.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WGS icon
76
GeneDx Holdings
WGS
$2.69B
$9.1M 0.04%
70,000
+65,000
+1,300% +$8.92M
ETH
77
Grayscale Ethereum Staking Mini ETF Shares
ETH
$2.08B
$6.41M 0.03%
+228,340
New +$7.44M
PRME icon
78
Prime Medicine
PRME
$649M
$4.31M 0.02%
1,240,843
-3,509,157
-74% -$15.6M
OSCR icon
79
Oscar Health
OSCR
$9.64B
$3.79M 0.02%
264,000
-3,375,000
-93% -$58.4M
MDGL icon
80
Madrigal Pharmaceuticals
MDGL
$12.5B
$1.93M 0.01%
3,319
– –
SMC
81
Summit Midstream
SMC
$469M
$1.55M 0.01%
58,214
– –
NVAX icon
82
Novavax
NVAX
$1.52B
$1.31M 0.01%
195,000
-585,000
-75% -$4.41M
SDGR icon
83
Schrodinger
SDGR
$1.46B
$1.27M 0.01%
71,000
-213,000
-75% -$4.04M
TEVA icon
84
Teva Pharmaceuticals
TEVA
$44.2B
$1.25M 0.01%
40,000
-4,957,000
-99% -$122M
CAPR icon
85
Capricor Therapeutics
CAPR
$544M
$1.18M 0.01%
41,000
– –
ARWR icon
86
Arrowhead Research
ARWR
$12.6B
$1.05M ﹤0.01%
15,800
– –
ALVO icon
87
Alvotech
ALVO
$1.75B
$1.02M ﹤0.01%
199,675
– –
BTSG icon
88
BrightSpring Health Services
BTSG
$12.1B
$824K ﹤0.01%
22,000
– –
ROIV icon
89
Roivant Sciences
ROIV
$26.5B
$803K ﹤0.01%
37,000
– –
ARQT icon
90
Arcutis Biotherapeutics
ARQT
$3.16B
$755K ﹤0.01%
26,000
– –
AXSM icon
91
Axsome Therapeutics
AXSM
$10.9B
$731K ﹤0.01%
4,000
– –
COGT icon
92
Cogent Biosciences
COGT
$6.37B
$604K ﹤0.01%
17,000
– –
ALKS icon
93
Alkermes
ALKS
$8.25B
$582K ﹤0.01%
20,800
– –
INSM icon
94
Insmed
INSM
$27.2B
$522K ﹤0.01%
3,000
– –
KRYS icon
95
Krystal Biotech
KRYS
$10.6B
$493K ﹤0.01%
2,000
– –
PGNY icon
96
Progyny
PGNY
$2.02B
$462K ﹤0.01%
18,000
– –
TVTX icon
97
Travere Therapeutics
TVTX
$6.33B
$459K ﹤0.01%
12,000
– –
HQY icon
98
HealthEquity
HQY
$8.73B
$458K ﹤0.01%
5,000
– –
CELC icon
99
Celcuity
CELC
$4.65B
$399K ﹤0.01%
+4,000
New +$329K
OMER icon
100
Omeros
OMER
$1.32B
$395K ﹤0.01%
+23,000
New +$198K
2 3
4
5 6

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Farallon Capital Management's Q4 2025 Portfolio in Review

As of Q4 2025, Farallon Capital Management held 175 positions worth $23.1B, down 5.4% from $24.4B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Farallon Capital Management withdrew a net $3.13B in Q4 2025, closing 21 positions and reducing 37 holdings. Its most notable exit was Autodesk, an estimated $528M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 41% of assets, up from 33% a quarter earlier, followed by Technology and Financials.

Against the trend, Farallon Capital Management opened a new position in Electronic Arts worth $1.03B.

  • Farallon Capital Management's largest Q4 2025 buy was Electronic Arts: 5,035,000 shares worth $1.03B.
  • Farallon Capital Management added most to Boston Scientific in Q4 2025, an estimated $264M increase.
  • Farallon Capital Management's biggest Q4 2025 reduction was Thermo Fisher Scientific, cutting an estimated $352M.
  • Farallon Capital Management fully exited Autodesk in Q4 2025, selling an estimated $528M.
  • Farallon Capital Management's ten largest holdings make up 44% of its $23.1B portfolio in Q4 2025.
  • Farallon Capital Management opened 31 new positions and closed 21 in Q4 2025.
  • Farallon Capital Management's portfolio value fell 5.4% quarter-over-quarter to $23.1B.

Based on Farallon Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.